Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: A population-based study

BMC Psychiatry

Volumn 14, Issue 1, 2014, Pages

  Sicras Mainar, Antoni ^a   Maurino, Jorge ^b   Ruiz Beato, Elena ^c   Navarro Artieda, Ruth ^d  

^a Badalona Serveis Assistencials SA   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^c Roche Farma SA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Electronic medical records; Healthcare costs; Negative symptoms; Resource use; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; HYPNOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; BLUNTED AFFECT; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIA; ELECTRONIC MEDICAL RECORD; EMOTIONAL DISORDER; EMOTIONAL WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MASCULINITY; MIDDLE AGED; MOTOR RETARDATION; NEGATIVE SYNDROME; OBESITY; OUTPATIENT; POLYPHARMACY; POSITIVE AND NEGATIVE SYNDROME SCALE; PREVALENCE; PRIMARY MEDICAL CARE; PRODUCTIVITY; PSYCHOSOCIAL WITHDRAWAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SOCIAL AVOIDANCE BEHAVIOR; SOCIAL INTERACTION; SPAIN; YOUNG ADULT; APATHY; ECONOMICS; EPIDEMIOLOGY; LONGITUDINAL STUDY; MENTAL HEALTH SERVICE; PSYCHOLOGY; SEX DIFFERENCE; UTILIZATION;

ADULT; APATHY; FEMALE; HEALTH CARE COSTS; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; OUTPATIENTS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS; SPAIN;

EID: 84905962901     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-014-0225-8     Document Type: Article

References (31)

1. Torres-Gonza´lez F, Ibanez-Casas I, Saldivia S, Ballester D, Grando´n P, Moreno-Ku¨stner B, Xavier M, Go´mez-Beneyto M. Unmet needs in the management of schizophrenia. Neuropsychiatr Dis Treat 2014, 10:97-110. 24476630.
2. Saha S, Chant D, McGrath J. Meta-analyses of the incidence and prevalence of schizophrenia: conceptual and methodological issues. Int J Methods Psychiatr Res 2008, 17:55-61. 18286464.
3. Garci´a-Portilla MP, Bobes J. The new challenge in identifying the negative syndrome of schizophrenia. Rev Psiquiatr Salud Ment 2013, 6:141-143. 24176303.
4. Bobes J, Arango C, Garcia-Garcia M, Rejas J. CLAMORS Study Collaborative Group: prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry 2010, 71:280-286. 19895779.
5. Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol 2014, 24:645-692. 24820238.
6. Arango C, Garibaldi G, Marder SR. Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res 2013, 150:346-352. 23938176.
7. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res 2012, 137:147-150. 22316568.
8. Rabinowitz J, Berardo CG, Bugarski-Kirola D, Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res 2013, 150:339-342. 23899997.
9. Strauss GP, Sandt AR, Catalano LT, Allen DN. Negative symptoms and depression predict lower psychological well-being in individuals with schizophrenia. Compr Psychiatry 2012, 53:1137-1144. 22770716.
10. Hunter R, Barry S. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. Eur Psychiatry 2012, 27:432-436. 21602034.
11. U¨c¸ok A, Gorwood P, Karadayi{dotless} G. EGOFORS: employment and its relationship with functionality and quality of life in patients with schizophrenia: EGOFORS Study. Eur Psychiatry 2012, 27:422-425. 21592736.
12. Salize HJ, McCabe R, Bullenkamp J, Hansson L, Lauber C, Martinez-Leal R, Reinhard I, Ro¨ssler W, Svensson B, Torres-Gonzalez F, van den Brink R, Wiersma D, Priebe S. Cost of treatment of schizophrenia in six European countries. Schizophr Res 2009, 111:70-77. 19401265.
13. Oliva-Moreno J, Lo´pez-Bastida J, Osuna-Guerrero R, Montejo-Gonza´lez AL, Duque-Gonza´lez B. The costs of schizophrenia in Spain. Eur J Health Econ 2006, 7:182-188. 16850333.
14. Charrier N, Chevreul K, Durand-Zaleski I. The cost of schizophrenia: a literature review. Ence´phale 2013, 39(Suppl 1):S49-S56. 23351935.
15. Aranda-Reneo I, Oliva-Moreno J, Vilaplana-Prieto C, Hidalgo-Vega A, Gonza´lez-Domi´nguez A. Informal care of patients with schizophrenia. J Ment Health Policy Econ 2013, 16:99-108. 24327480.
16. Mohr PE, Cheng CM, Claxton K, Conley RR, Feldman JJ, Hargreaves WA, Lehman AF, Lemert LA, Mahmoud R, Marder SR, Neumann PJ. The heterogeneity of schizophrenia in disease states. Schizophr Res 2004, 71:83-95. 15374576.
17. Knapp M, McCrone P, Leeuwenkamp O. Associations between negative symptoms, service use patterns, and costs in patients with schizophrenia in five European countries. Clin Neuropsychiatry 2008, 5:195-205.
18. American Psychiatric Association, American Psychiatric Association, Task Force on DSM-IV Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 2000, American Psychiatric Association, Washington DC.
19. Marder SR, Daniel DG. Methodological issues in negative symptom trials. Schizophr Bull 2011, 37:250-254. 21270473.
20. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997, 58:538-546. 9448657.
21. Lamberts H, Wood M, Hofmans-Okkes I. The International Classification of Primary Care in the European Community: with a Multi-Language Layer 1993, Oxford University Press, Oxford: New York.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383. 3558716.
23. Weiner JP, Starfield BH, Steinwachs DM, Mumford LM. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care 1991, 29:452-472. 1902278.
24. WHO Collaborating Centre for Drug Statistics Methodology: Guidelines for ATC Classification and DDD Assignment 2013. Oslo; 2012..
25. The Spanish Institute of Statistics (INE):Annual Labor Cost Survey 2011,
26. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed?. BMJ 2000, 320:1197-1200. 10784550.
27. Fervahaa G, Foussias G, Remington G: Impact of primary negative symptoms on functional outcomes in schizophrenia. Eur Psychiatry 2014, Mar 14 [Epub ahead of print]..
28. Becker T, Knapp M, Knudsen HC, Schene A, Tansella M, Thornicroft G, Vazquez-Barquero JL. The epsilon study - a study of care for people with schizophrenia in five European centres. World Psychiatry 2002, 1:45-47. 16946822.
29. Motheral B, Brooks J, Clark MA, Crown WH, Davey P, Hutchins D, Martin BC, Stang P. A checklist for retrospective database studies - report of the ISPOR task force on retrospective databases. Value Health 2003, 6:90-97. 12641858.
30. Daniel DG. Issues in selection of instruments to measure negative symptoms. Schizophr Res 2013, 150:343-345. 23899996.
31. Marder SR, Alphs L, Anghelescu IG, Arango C, Barnes TRE, Caers I, Daniel DG, Dunayevich E, Fleischhacker WW, Garibaldi G, Green MF, Harvey PD, Kahn RS, Kane JM, Keefe RSE, Kinonn B, Leucht S, Lindenmayer JP, Malhotra AK, Stauffer V, Umbricht D, Wessnes K, Kapur S, Rabinowitz J. Issues and perspectives in designing clinical trials for negative symptoms in Schizophrenia. Schizophr Res 2013, 150:328-333. 24028744.